UNCY Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.472

-81.86%

0.378

-175.6%

1.162

-323.46%

Estimates Revision

The market is revising No Change the revenue expectations for Unicycive Therapeutics, Inc. (UNCY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.19%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-21.51%

In Past 3 Month

Stock Price

Go Up

+39.19%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast UNCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNCY is 36.60 USD with a low forecast of 21.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

36.60

High

60.00

Current: 0.000

Low

21.00

Averages

36.60

High

60.00

H.C. Wainwright

NULL -> Buy

maintain

$9 -> $22

2025-10-29

Reason

H.C. Wainwright

Price Target

$9 -> $22

2025-10-29

maintain

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on Unicycive Therapeutics to $22 from $9 and keeps a Buy rating on the shares. The believes the company's regulatory overhang has been revolved after its Type A meeting with the FDA. Unicycive plans to file a response to the complete response letter by year-end and expects a decision in the first half of 2026, the analyst tells investors in a research note.

Benchmark

Speculative Buy

maintain

$3 -> $21

2025-09-15

Reason

Benchmark

Price Target

$3 -> $21

2025-09-15

maintain

Speculative Buy

Reason

Benchmark raised the firm's price target on Unicycive Therapeutics to $21 from $3 and keeps a Speculative Buy rating on the shares, noting that the firm's new price target reflects a 1:10 reverse split and an updated discount rate after Unicycive said that it plans to complete a Type A meeting with the FDA to gain alignment on the best strategy to resolve the remaining issues outlined in the complete response letter for the oxylanthanum carbonate New Drug Application.

Lucid Capital

Elemer Piros

Buy

initiated

$12

2025-06-04

Reason

Lucid Capital

Elemer Piros

Price Target

$12

2025-06-04

initiated

Buy

Reason

Lucid Capital analyst Elemer Piros initiated coverage of Unicycive Therapeutics with a Buy rating and $12 price target. The company could launch oxylanthanum carbonate in the second half of 2025, one of the first innovative products in over a decade for the treatment of hyperphosphatemia, the analyst tells investors in a research note. The firm says Unicycive is building a "comprehensive" drug portfolio for chronic kidney disease and acute kidney injury.

H.C. Wainwright

Buy

initiated

2025-05-27

Reason

H.C. Wainwright

Price Target

2025-05-27

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Unicycive Therapeutics with a Buy rating and $9 price target. Unicycive is a clinical stage biotechnology company developing novel therapies for treating kidney diseases, the analyst tells investors in a research note. The firm expects a positive decision by the FDA for the company's leading clinical candidate, oxylanthanum carbonate, for lowering high phosphate levels or hyperphosphatemia in chronic kidney disease patients undergoing dialysis and expects management to launch the drug by the end of 2025.

Guggenheim

Vamil Divan

Strong Buy

Initiates

2025-04-21

Reason

Guggenheim

Vamil Divan

Price Target

2025-04-21

Initiates

Strong Buy

Reason

Guggenheim initiated coverage of Unicycive Therapeutics with a Buy rating and $6 price target.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-04-11

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-04-11

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Unicycive Therapeutics Inc (UNCY.O) is 1.59, compared to its 5-year average forward P/E of -0.46. For a more detailed relative valuation and DCF analysis to assess Unicycive Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.46

Current PE

1.59

Overvalued PE

6.55

Undervalued PE

-7.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6055.47

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

22432.39

Undervalued EV/EBITDA

-34543.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.42

Current PS

1.12

Overvalued PS

16.53

Undervalued PS

-7.69

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

UNCY News & Events

Events Timeline

No data

News

9.0

2025-12-29NASDAQ.COM

Unicycive Resubmits NDA for OLC to Treat Hyperphosphatemia in CKD Patients

9.0

2025-12-29Globenewswire

Unicycive Resubmits OLC NDA to FDA, Cash Runway Until 2027

9.0

2025-12-29Newsfilter

Unicycive Resubmits OLC NDA to FDA, Cash Runway Until 2027

People Also Watch

Frequently Asked Questions

What is Unicycive Therapeutics Inc (UNCY) stock price today?

The current price of UNCY is 6.18 USD — it has increased 0.98 % in the last trading day.

What is Unicycive Therapeutics Inc (UNCY)'s business?

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

What is the price predicton of UNCY Stock?

What is Unicycive Therapeutics Inc (UNCY)'s revenue for the last quarter?

Unicycive Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Unicycive Therapeutics Inc (UNCY)'s earnings per share (EPS) for the last quarter?

Unicycive Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -28.26 % YoY.

What changes have occurred in the market's expectations for Unicycive Therapeutics Inc (UNCY)'s fundamentals?

How many employees does Unicycive Therapeutics Inc (UNCY). have?

Unicycive Therapeutics Inc (UNCY) has 22 emplpoyees as of January 10 2026.

What is Unicycive Therapeutics Inc (UNCY) market cap?

Today UNCY has the market capitalization of 132.82M USD.